CH Biotech R&D Co., Ltd. (TPE:6534)
Taiwan · Delayed Price · Currency is TWD 93.80
+1.20 (1.30%)
Dec 3, 2025, 1:35 PM CST
CH Biotech R&D Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 1,766 | 1,636 | 1,515 | 1,434 | 1,019 | 702.19 | Upgrade | |
Revenue Growth (YoY) | 17.43% | 7.98% | 5.63% | 40.81% | 45.05% | -16.47% | Upgrade |
Cost of Revenue | 277.49 | 270.92 | 254.73 | 299.52 | 170.56 | 112.18 | Upgrade |
Gross Profit | 1,489 | 1,365 | 1,260 | 1,135 | 847.95 | 590.01 | Upgrade |
Selling, General & Admin | 499.08 | 459.16 | 389 | 351.12 | 267.2 | 251.6 | Upgrade |
Research & Development | 387.97 | 363.36 | 305.24 | 272.41 | 221.48 | 193.34 | Upgrade |
Operating Expenses | 897.9 | 822.52 | 694.24 | 623.54 | 488.68 | 444.93 | Upgrade |
Operating Income | 590.81 | 542.3 | 565.86 | 511.06 | 359.27 | 145.07 | Upgrade |
Interest Expense | -17.21 | -15 | -16.81 | -16.81 | -13.9 | -22.74 | Upgrade |
Interest & Investment Income | 12.42 | 18.8 | 17.22 | 5.12 | 0.6 | 1.52 | Upgrade |
Earnings From Equity Investments | -1.66 | -0.26 | -0.05 | - | - | - | Upgrade |
Currency Exchange Gain (Loss) | -53.47 | 39.58 | 7.18 | 62.28 | -12.15 | -24.51 | Upgrade |
Other Non Operating Income (Expenses) | 4.94 | 5.54 | 4.46 | 3.59 | 25.69 | 26.84 | Upgrade |
EBT Excluding Unusual Items | 535.82 | 590.96 | 577.86 | 565.23 | 359.5 | 126.19 | Upgrade |
Gain (Loss) on Sale of Assets | -0.09 | 0.31 | 1.07 | 0.57 | 0.11 | 0.04 | Upgrade |
Other Unusual Items | - | 1.69 | - | - | 0.04 | 1.17 | Upgrade |
Pretax Income | 535.73 | 592.96 | 578.93 | 565.8 | 359.65 | 127.39 | Upgrade |
Income Tax Expense | 96.67 | 117.27 | 115.64 | 100.37 | 68.15 | 27.23 | Upgrade |
Earnings From Continuing Operations | 439.07 | 475.69 | 463.29 | 465.42 | 291.5 | 100.16 | Upgrade |
Minority Interest in Earnings | 0.26 | 0.7 | - | - | - | - | Upgrade |
Net Income | 439.33 | 476.39 | 463.29 | 465.42 | 291.5 | 100.16 | Upgrade |
Net Income to Common | 439.33 | 476.39 | 463.29 | 465.42 | 291.5 | 100.16 | Upgrade |
Net Income Growth | 15.24% | 2.83% | -0.46% | 59.66% | 191.03% | -47.41% | Upgrade |
Shares Outstanding (Basic) | 103 | 103 | 97 | 97 | 97 | 97 | Upgrade |
Shares Outstanding (Diluted) | 103 | 103 | 98 | 99 | 98 | 98 | Upgrade |
Shares Change (YoY) | 1.56% | 5.50% | -0.77% | 0.54% | 0.44% | -0.37% | Upgrade |
EPS (Basic) | 4.27 | 4.63 | 4.76 | 4.79 | 3.00 | 1.03 | Upgrade |
EPS (Diluted) | 4.25 | 4.61 | 4.73 | 4.72 | 2.97 | 1.03 | Upgrade |
EPS Growth | 13.22% | -2.54% | 0.21% | 58.92% | 189.44% | -47.08% | Upgrade |
Free Cash Flow | 163.81 | -49.98 | 545.47 | 585.08 | 192.43 | 125.03 | Upgrade |
Free Cash Flow Per Share | 1.59 | -0.48 | 5.57 | 5.93 | 1.96 | 1.28 | Upgrade |
Dividend Per Share | 4.100 | 4.100 | 4.090 | 3.880 | 1.304 | 0.435 | Upgrade |
Dividend Growth | 14.21% | 0.24% | 5.41% | 197.48% | 199.98% | -52.27% | Upgrade |
Gross Margin | 84.29% | 83.44% | 83.18% | 79.11% | 83.25% | 84.02% | Upgrade |
Operating Margin | 33.45% | 33.15% | 37.35% | 35.64% | 35.27% | 20.66% | Upgrade |
Profit Margin | 24.87% | 29.12% | 30.58% | 32.45% | 28.62% | 14.26% | Upgrade |
Free Cash Flow Margin | 9.28% | -3.06% | 36.01% | 40.80% | 18.89% | 17.80% | Upgrade |
EBITDA | 770.46 | 704.78 | 703.17 | 628.06 | 435.89 | 223.8 | Upgrade |
EBITDA Margin | 43.62% | 43.09% | 46.42% | 43.79% | 42.80% | 31.87% | Upgrade |
D&A For EBITDA | 179.65 | 162.48 | 137.31 | 117.01 | 76.62 | 78.73 | Upgrade |
EBIT | 590.81 | 542.3 | 565.86 | 511.06 | 359.27 | 145.07 | Upgrade |
EBIT Margin | 33.45% | 33.15% | 37.35% | 35.64% | 35.27% | 20.66% | Upgrade |
Effective Tax Rate | 18.04% | 19.78% | 19.98% | 17.74% | 18.95% | 21.38% | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.